OncoCyte Corporation (OCX)
- Previous Close
2.4550 - Open
2.5100 - Bid --
- Ask --
- Day's Range
2.2850 - 2.5100 - 52 Week Range
2.0800 - 6.2000 - Volume
40,560 - Avg. Volume
56,538 - Market Cap (intraday)
32.812M - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
-- - EPS (TTM)
-3.3700 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.90
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
www.oncocyte.com43
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: OCX
Performance Overview: OCX
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OCX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OCX
Valuation Measures
Market Cap
32.75M
Enterprise Value
26.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.50
Price/Book (mrq)
1.60
Enterprise Value/Revenue
17.42
Enterprise Value/EBITDA
-1.13
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.91%
Return on Equity (ttm)
-76.26%
Revenue (ttm)
1.5M
Net Income Avi to Common (ttm)
-25.8M
Diluted EPS (ttm)
-3.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
9.43M
Total Debt/Equity (mrq)
11.21%
Levered Free Cash Flow (ttm)
-6.9M